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Abstract
Background: Although parotid-sparing IMRT decreased the dose distribution of parotid, parotid region recurrence
has been reported. Prophylactic irradiation in parotid area would be necessary in patients with high risk of parotid
lymph node metastasis (PLNM). This study was to detect the high-risk factors of PLNM in nasopharyngeal
carcinoma.
Methods: This was a 1:2 case-control study. All patients in this study were newly diagnosed NPC with N2-3
classification from January 2005 to December 2012. Cases were 22 sides with ipsilateral PLNM. Controls were 44
patients who were randomly selected from N2-3 disease in database.
Results: 20/1096 (1.82 %) NPC patients were found PLNM. Sum of the longest diameter for multiple lymph nodes
(SLD) in level II was larger in case group than that in control group (6.0 cm vs. 3.6 cm, p = 0.003). Level II lymph node
necrosis, level Va/b involvement, and rare neck areas involvement were more common in case group (p = 0.016, p = 0.
034, and p < 0.001, respectively). RPN, level III, and level IV metastases showed no significant difference between the
two groups. Multivariate analysis in logistic regression showed that only SLD ≥5 cm in II area (OR = 4.11, p = 0.030) and
rare neck areas involvement (OR = 3.95, p = 0.045) were associated with PLNM in NPC patients.
Conclusions: PLNM was an uncommon event in NPC patients. SLD ≥5 cm in level II and involvement in rare-neck
areas may be potentially high-risk factors for PLNM. Sparing parotid in IMRT was not recommended for NPC patients
with high risks of PLNM.
Keywords: Nasopharyngeal carcinoma, Periparotid lymph node metastasis, Risk factors, Case-control study
Abbreviations: AJCC, American Joint Committee on Cancer; AUC, Area under curve; ENS, Extra-nodal neoplastic
spread; FNA, Fine needle aspiration; NPC, Nasopharyngeal carcinoma; PLNM, Parotid lymph node metastasis;
ROC, Receiver operating characteristic curve; RPN, Retropharyngeal lymph node; SLD, Sum of the longest diameter for
multiple lymph nodes
Background
Nasopharyngeal carcinoma (NPC) is usually presented
with regional lymph node metastasis. And retropharyn-
geal nodes and level II were the most commonly in-
volved regions, with the incidence of 69 % and 70 %,
respectively [1]. However, parotid lymph nodes (PLNs)
were rarely involved.
In 2013, DAHANCA, EORTC, HKNPCSG, NCIC
CTG, NCRI, RTOG, TROG consensus guidelines re-
garding the delineation of the neck node levels for head
and neck tumors has defined the parotid lymph node
group as level VIII, which included the subcutaneous
pre-auricular nodes, the superficial and deep intraparo-
tid nodes, and the subparotid nodes [2]. In anatomy,
parotid lymph node receive efferent lymphatic from the
frontal and temporal skin, the eyelids, the conjunctiva,
the external auditory canal, the tympanum, the nasal
cavities, the root of the nose, the nasopharynx, and the
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Eustachian tube. Theoretically, nasopharyngeal carcin-
oma is at risk of harboring parotid lymph node metasta-
sis (PLNM). However, the reported incidence of PLNM
in NPC patients was only 0.6–3.0 % [3–7]. Direct lymph-
atic drainage from nasopharynx to parotid was to be
questioned.
Radiotherapy is the mainstay of definitive treatment mo-
dality for nasopharyngeal carcinoma. In conventional two-
dimensional treatment era (Ho’s technique), lateral oppos-
ing fields encompassed the parotids in the irradiation vol-
ume. Mean dose of parotid was 55.3Gy [8] and ≥ grade II
late xerostomia was 29.7 % [9]. With the development of
radiation technique, parotid-sparing IMRT has decrease
the dose distribution of parotid [10, 11] and improved pa-
tients’ quality of life, particularly xerostomia recovery [12].
However, with the use of parotid-sparing IMRT, parotid
region recurrence has been reported. In 2007, Luo et al.
[13] has showed 3 cases of parotid recurrence in NPC pa-
tients after IMRT. In 2013, Cao et al. reported 10 cases of
periparotid recurrence and the incidence of parotid recur-
rence was 1.4 % [14]. Periparotid recurrence may be sup-
posed to be related to sparing parotid in IMRT.
Although parotid lymph node metastasis is an uncom-
mon event in NPC patients, and the target definition
and coverage for patients treated with IMRT for parotid
sparing is adequate, questions remain pertaining to what
high-risk factors would lead to parotid lymph node me-
tastasis in NPC patients and whether the target defin-
ition of parotid sparing should be adjusted in patients




We retrospectively reviewed the archives of 1096 pa-
tients with NPC who underwent IMRT in Cancer
Hospital of Chinese Academy of Medical Science
from January 2005 to December 2012. Twenty (1.8 %)
patients were shown parotid lymph nodes metastasis
when newly diagnosed. And 3 patients were found
simultaneously bilateral parotid lymph node involve-
ment. Of the 20 PLNM patients, 10 patients were di-
agnosed with fine needle aspiration (FNA) and
cytological biopsy. And the other 10 patients were di-
agnosed with contrast-enhanced MR imaging and
Doppler ultrasonography. According to the 7th edition
of American Joint Committee on Cancer (AJCC) sta-
ging system, 19/20 (95.0 %) patients were N2-3 classi-
fication, which was significantly higher than 616/1096
(56.2 %) in whole NPC patients (p < 0.001). However,
in the subset of the N2-3 NPC patients, the rate of
PLNM was only 3.3 %. N classification alone was not
enough to select the high-risk PLNM patients.
Study design
This was a 1:2 case-control study. All patients in this
study were newly diagnosed NPC with N2-3 classifica-
tion. One PLNM patients was removed because of the
N1 disease. Case group was designed as the ipsilateral
neck with PLNM, including 22 cases (totally 19 patients
and 3 patients with bilateral PLNM). 44 NPC patients
were randomly selected from the N2-3 patients without
PLNM. And the control group was designed as the ipsi-
lateral neck with primary tumor center, or the side with
heavier neck disease. This study was performed after ap-
proval by the institutional review board and ethics com-
mittee. And informed consents from each participant
were obtained.
MR imaging was performed in all patients. And the
images were separately reevaluated by two radiologists
and one radiation oncologist. The node level was divided
according to the updated consensus guidelines in 2013
[2]. As the 3rd echelon of draining nodes in NPC [1], we
regarded the level Ia/b, Vc (the lateral supraclavicular
nodes), and VIa/b as the rare-neck areas. Information of
the regional lymph nodes were collected, including
lymph node involvement, Sum of the largest diameter
for multiple lymph nodes (SLD) in each level, extra-
nodal neoplastic spread (ENS), and necrosis. Lymph
node involvement was determined by multiple criteria
[15], including (a) shortest transverse diameter in the
largest plane of cervical node > 10 mm and > 5 mm for
lateral RPN, and any node seen in the median RPN; (b)
central necrosis, extra-nodal neoplastic spread; (c) three
or more contiguous and confluent lymph nodes, with
shortest transverse diameter > 8 mm. SLD meant sum of
the largest diameter in transverse, sagittal, or coronal
plane for multiple lymph nodes. And confluent lymph
nodes were evaluated as single one.
Statistical analysis
SPSS 16.0 software package was used for statistical ana-
lysis. The distribution of exposure factors between case
and control groups was evaluated using t test or Wil-
coxon rank sum test for quantitative variables, and the
chi-square test or Fisher exact test for categorical vari-
ables. Receiver operating characteristic (ROC) curve
analysis was used to evaluate different cut-off points for
SLD to discriminate case or control group. Binary logis-
tic regression was used to estimate the correlation be-
tween multiple exposure factors and the PLNM. With a
two-sided test, p value of <0.05 was considered statisti-
cally significant.
Results
Median age of the patients in this study was 42 (range, 9–
67) years. All patients had WHO type II or III disease. And
41/63 (65.1 %) patients were T3-4 disease. 47/63 (74.6 %)
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patients came to hospital because of a chief complaint of
the mass in neck. Table 1 showed the clinical features of pa-
tients. And there were no significant difference in clinical
features between the case and control groups.
Parotid lymph nodes metastasis
Totally, there were 48 positive lymph nodes found in the
22 cases of PLNM. Of the 48 positive lymph nodes, 21
nodes were located in superficial intraparotid, 13 nodes
in subparotid, 11 nodes in deep intraparotid, and 3
nodes in pre-auricular area, respectively. The median of
largest transverse diameter of nodes in parotid was
1.0 cm (range, 0.4–3.1 cm). And the median of shortest
transverse diameter in the largest plane of parotid node
was 0.7 cm (range, 0.4–2.0 cm). There were 10 cases of
ENS and 8 cases of necrosis in metastatic parotid nodes.
Fig. 1 showed one NPC patient with parotid lymph
nodes metastasis, and the extensive lymphadenopathy
can be seen in ipsilateral neck.
Regional lymph nodes metastasis in case and control
groups (Table 2)
Involvement of RPN was found in 53/66 (80.3 %) sides.
ENS and necrosis in RPN were found in 43/66 (65.2 %)
and 20/66 (30.3 %) sides, respectively. RPN involvement,
ENS, necrosis, and SLD showed no significant difference
in case and control group.
Level II contained IIa and IIb subareas. All patients in
this study were involved with level II. ENS and necrosis
in level II were found in 59/66 (89.4 %) and 44/66
(66.7 %) sides. And level II necrosis in case group was
significantly higher than that in control group (86.4 %
vs. 56.8 %, p = 0.016). The median of SLD in level II was
4.5 cm (range, 1.0–14.7 cm) in the sets. And the SLD of
level II in case group was larger than that in control
group (median, 6.0 vs. 3.6 cm, p = 0.003).
Level III involvement, ENS, and necrosis was found in
45/66 (68.2 %), 33/66 (50.0 %), and 14/66 (21.2 %) sides
in this study, respectively. The median of SLD in level
III was 0.9 cm (range, 0–7.2 cm). And no significant dif-
ference in level III involvement, ENS, necrosis, and SLD
was found in case and control groups.
Level IV involvement, ENS, and necrosis were found
in 21/66 (31.8 %), 15/66 (22.7 %), 4/66 (6.1 %) sides in
this study, respectively. And no significant difference in
level IV involvement, ENS, necrosis, and SLD was found
in case and control groups.
Level Va/b involvement was found in 19/66 (28.8 %)
sides in this study. And the rate of level Va/b involve-
ment was higher in case group than that in control
group (45.5 % vs. 20.5 %, p = 0.034). There was no sig-
nificant difference in ENS, necrosis, and SLD in level
Va/b between the two groups.
Rare-neck areas in this study contained level Ia/b, Vc
and VIa/b. And level Ia/b, Vc and VIa/b involvement
were found in 6, 8, and 2 sides in case group, respect-
ively. The rate of rare-neck areas involvement was
higher in case group than that in control group (54.5 %
vs. 13.6 %, p < 0.001).
Multivariate analysis
ROC curve was used to determine the most suitable cut-
off SLD in level II (AUC =0.73, p = 0.003). 5.0 cm (≥5.0
vs. <5.0) was selected as the cut-off point with sensitivity
of 72.7 % and specificity of 72.7 %. Binary logistic regres-
sion model was used to analyze the high-risk factors of
PLNM in multivariate analysis. When SLD ≥5.0 cm in
level II, necrosis in level II, involvement in level Va/b,
and involvement in rare-neck areas were included into
analysis, only SLD ≥5.0 cm in level II (OR = 4.11, 95 % CI
1.15-15.73, p = 0.030) and rare-neck areas involvement
(OR = 3.95, 95 % CI 1.03-15.09, p = 0.045) were associated
with PLNM in NPC patients (Table 3).
Discussion
PLNM was thought to be an uncommon event in NPC
patients. It has been reported that the incidence of PLNM
was 0.6 % ~ 3.0 % in whole NPC patients [3–7, 16]. And
similarly, the incidence of PLNM was 1.8 % in whole pa-
tients and was 3.3 % in N2-3 NPC patients in this study.
According to the size of metastatic nodes in parotid, it
should be highly suspected that any single lymph node of
parotid with largest transverse diameter ≥ 0.5 cm or mul-
tiple nodes with borderline size in NPC patients who were
Table 1 Clinical features of patients in case and control groups






Median 42.0 46.0 42.0
Range 9-67 9-66 16-67
Sex 1.000
Male 49 (77.8) 15 34
Female 14 (22.2) 4 10
Histology 0.979
Differentiated 33 (52.4) 10 23
Undifferentiated 30 (47.6) 9 21
T stage 0.346
T1-2 22 (34.9) 5 17
T3-4 41 (65.1) 14 27
Mass in neck (C.C.)b 0.142
Yes 47 (74.6) 17 30
No 16 (25.4) 2 14
aControl group: N2-3 NPC patients without periparotid lymph node metastasis
bMass in neck (C.C.), a chief complaint of the mass in neck
*p < 0.05
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simultaneously suffered from heavy lymph node invasion
in ipsilateral neck. And the nodes in parotid should be
confirmed by ultrasonographically guided FNA or CT-
guided biopsy. In this study, 48 lymph nodes in 22
parotids were found to be positive, and superficial intra-
parotid was the most frequently involved subarea (43.8 %).
10 (45.5 %) parotids showed multiple subareas invasion.
Therefore, if there were PLNMs, the whole parotid may
be supposed to be in target volume.
Retropharyngeal nodes were the first echelon of nodal
metastases in NPC and the incidence of RPN involve-
ment was 75.1–94.0 % in node-positive NPC [3–7, 16].
However, RPN involvement, ENS, necrosis, and SLD
showed no significant difference between the two
groups. Our findings seemed not to support the theory
that tumor can reach the parotid gland directly via the
RPNs [17]. In fact, except for parapharyngeal space in-
volvement, there were no correlations between RPN me-
tastasis and surrounding invasions [18]. Direct lymphatic
spread from RPN to parotid tissue was questioned.
Like RPNs, level II was also proved to be the first-
echelon nodal metastasis for NPC. And the previously
reported incidence of level II involvement was 75.1–
95.5 % in node-positive NPC patients [3–6]. Our finding
showed 100 % involvement in level II in both groups.
Level II involvement alone was not enough to predict
the PLNM. The parotid gland contains an extensive
lymphatic capillary plexus. However, patterns of metas-
tasis to the parotid nodes were hardly distinguished from
a recognized drainage area and from widespread meta-
static disease in the neck and involvement by retrograde
extension [19]. Anatomically, lymphatics of parotid
drained along the retromandibular vein to superficial
nodes along the outer surface of the sternocleidomastoid
muscle, and then partially drained into upper nodes of
the deep cervical chain [20]. In 2009, Pan et al. [21]
showed drawings of the lymphatic pathways from
nasopharynx. Lymphatic vessels from nasopharynx
drained in two general directions, lateral pharyngeal and
retropharyngeal directions. The former one descended
along the pharyngeal wall in the parapharyngeal fat tis-
sue to reach its first tier lymph node, level II node,
which was situated on the lateral side of the external ca-
rotid artery [21]. No direct lymphatic drainage was
found from nasopharynx to parotid area in Pan’s study.
However, we suppose that level II nodes that connected
superficial and deep cervical nodes may play crucial role
in PLNM from retrograde extension. Our findings
showed clinical evidences that PLNM was closely corre-
lated with SLD and necrosis of level II. NPC patients
with heavy disease in level II may cause the blockage of
the normal routes of lymphatic drainage and induce
retrograde tumor spread to parotid lymph nodes. SLD
≥5.0 cm and necrosis may be indicators of heavy disease
of level II and be potential high-risk factors for PLNM.
Level III, IV, and Va/b represented second-echelon of
nodal metastases in NPC with the incidence of involve-
ment of 44.9 %, 11.2 %, and 26.7 %, respectively [1].
Lymph node metastases progressed in an orderly way
and skip metastases were rarely found [3, 6]. Our find-
ings showed that the incidence of level III, IV, and Va/b
involvement in case group were 72.7 %, 45.5 %, and
45.5 %, respectively. Caudal (level III/IV) and posterior
(level V) lymphatic spreads were higher involved in our
study than that in previous results [3–6]. Although level
III involvement showed no significant difference in case
and control groups, Level IV and Va/b involvement ap-
peared to be marginal and significant difference, respect-
ively. Previous studies postulated that widespread
metastatic disease in the neck may count for PLNM, but
no evidence listed [6, 7]. Our results showed that the
number of involved levels was correlated with PLNM
and that multiple levels (≥4 levels) involvement may be a
potential high-risk factor for PLNM (Table 2).
Rare-neck areas in this study were defined as level Ia/
b, Vc, and VIa/b, which all belonged to third-echelon of
nodal metastases in NPC [1]. The incidence of rare-neck
areas involvement was higher in case group than that in
Fig. 1 One NPC patient with superficial and deep intraparotid nodes metastasis. a. Transverse T2WI; b. Transverse T1WI with contrast
enhancement; c. Sagittal T1WI with contrast enhancement in the ipsilateral neck
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control group (54.5 % vs. 13.6 %, p < 0.001). 3.1–4.3 %
cases with level Ib involvement has been reported in
previous study and all patients were simultaneously ac-
companied with level II lymphadenopathy [3, 16]. Wang
reported 1.8 % level Vc involvement in N-positive NPC
patients. And level Vc metastasis was associated with
multiple levels involvement and the total number of
positive nodes was always more than seven. To a large
extent, 3th-echelon lymph nodes metastasis in NPC was
associated with extensively adjacent neck disease. Par-
otid lymph node was also regarded as the third-echelon
of draining nodes in NPC [1]. Probably because it was a
surrogate marker of extensive ipsilateral nodal disease,
the rare-neck areas involvement was closely correlated
with PLNM in this study.
Multivariate analysis showed that SLD ≥5.0 cm in level
II (OR = 4.11, p = 0.030) and rare-neck areas involvement
(OR = 3.95, p = 0.045) were independent high-risk factors
Table 2 Ipsilateral neck lymph nodes metastasis in case and control groups
Variables Total No. (%) Cases(22 sides) Controls(44 sides)a p value*
RPNb
Involvement 53 (80.3) 20 33 0.229
SLDc 1.8 (0-5.5) 2.4(0-5.5) 1.5(0-4.7) 0.106
ENSd 43 (65.2) 17 26 0.144
Necrosis 20 (30.3) 6 14 0.705
Level II
Involvement 66 (100) 22 44 -
SLDc 4.5 (1.0-14.7) 6.0(1.5-14.7) 3.6(1.0-9.0) 0.003*
SLD≥ 5.0 cm 28 (42.4) 16 12 <0.001*
ENSd 59 (89.4) 21 38 0.409
Necrosis 44 (66.7) 19 25 0.016*
Level III
Involvement 45 (68.2) 16 29 0.575
SLDc 0.9 (0-7.2) 1.0(0-7.2) 0.8(0-3.8) 0.211
ENSd 33 (50.0) 10 23 0.602
Necrosis 14 (21.2) 4 10 0.915
Level IV
Involvement 21 (31.8) 10 11 0.093
SLDc 0.0 (0-6.9) 0.0(0-6.9) 0.0(0-2.0) 0.179
ENSd 15 (22.7) 7 8 0.213
Necrosis 4 (6.1) 2 2 0.596
Level Va/b
Involvement 19 (28.8) 10 9 0.034*
SLDc 0.0 (0-9.3) 0.0(0-9.3) 0.0(0-2.2) 0.299
ENSd 6 (9.1) 4 2 0.167
Necrosis 4 (6.1) 3 1 0.104
Rare-neck area involvemente
18 (27.3) 12 6 <0.001*
No. of involved levelsf
Median 2 .0(1-5) 3.5(1-5) 2.0(1-5) 0.045*
≥ 4 levels 17 (25.8) 11 6 0.001*
aControl group: The ipsilateral neck with primary tumor center or the side with heavier neck disease in the N2-3 NPC patients without PLNM
bRPN: Retropharyngeal lymph node
cSLD: Sum of the largest diameter for multiple lymph nodes in different neck levels. Median and range were listed in table
dENS: Extra-nodal neoplastic spread
eRare neck areas including level Ia/b, level Vc, and level VI in this study
fNo. of involved levels, when RPN was excluded and rare-neck areas were counted as one level
*p < 0.05
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of PLNM. Any patients with extensive tumor invasion
and suspected blockage of lymphatic drainage should be
emphasized to conduct parotid detection. In 2008, Can-
non reported two cases of periparotid recurrence in
NPC patients after definitive IMRT [22]. Both patients
had small subclinical periparotid nodules and multilevel
nodal disease in ipsilateral neck in pretreatment imaging.
The two relapsed nodes were both found in superficial
intraparotid that was situated outside of the field and re-
ceived doses less than 20Gy. In 2003, Chao et al. re-
ported 1 % marginal failure in the region adjacent to the
spared parotid gland following IMRT in head and neck
cancer [23], but no recommendation has been proposed
pertaining to prevention of periparotid failure. Our find-
ings in this study suggested that prophylactic irradiation
to the whole or part of the ipsilateral parotid may be ne-
cessary for NPC patients with high-risk factors of
PLNM.
High-risk factors of PLNM have been discussed for
the first time in this study. However, the results of this
study should be interpreted with caution, as this was a
case-control study of a small sample size. Although peri-
parotid failure was inferred to be related to parotid-
sparing IMRT, failure analysis was hard to carry out.
Further investigations of large sample from multiple
centers may be warranted.
Conclusion
To summarize, PLNM was an uncommon event and the
incidence was 1.8 % in NPC patients. Any enlarged sin-
gle lymph node of parotid with largest transverse diam-
eter ≥ 0.5 cm or multiple nodes with borderline size in
NPC patients who were simultaneously companied with
extensive ipsilateral nodal disease should be further
detected. SLD ≥5.0 cm in level II and involvement in
rare-neck areas may be potentially high-risk factors for
PLNM in NPC patients. Sparing parotid in IMRT was
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